MRNA, SRPT, and KRYS Phase 3 Data Will Shape XBI's 2026 Performance - 24/7 Wall St. S&P 5006,362.40 -2.11% Dow Jones45,108.10 -2.16% Nasdaq 10023,104.20 -2.34% Russell 20002,443.51 -2.47% SPDR S&P Biotech ETF (XBI) holds 150+ equal-weight positions and is up 46% over the past year, but faces near-term headwinds from FDA staffing cuts that could slow the regulatory approval pipeline that biotech valuations depend on. Moderna (MRNA) is the largest position at 2.3% weight and expects phase 3 norovirus and m ...

When you think of GLP-1s and investing, the two large pharmaceutical companies benefiting most from this trend may first come to mind. First, there's Novo Nordisk, the first to bring GLP-1 weight loss drugs to market, with Ozempic and Wegovy. Second, there's Eli Lilly, beating Novo Nordisk at its own game, with its Zepbound GLP-1 treatment.Several other big pharma companies, like Pfizer, have their own injectable and oral-based GLP-1 candidates. The market incumbents are also working on orally administered ...

IBRX INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that ImmunityBio, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit IBRX INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that ImmunityBio, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit Share SAN DIEGO--(BUSINESS WIRE)--The law firm of Robbins Geller Rudman & Dowd LLPannounces that purchasers or acquirers of ImmunityBio, Inc. (NASDAQ: IBRX) publicly traded secur ...

BlackSky ( BKSY ) managed to report a 4Q25 GAAP EPS of -$0.02, a figure that beat expectations by $0.16. Revenue, on the other hand, came in at $35 million, up about 16% since last year but missing estimates by about $2.1 million. TheI hold a Master’s degree in Cell Biology and began my career working for several years as a lab technician in a drug discovery clinic, where I gained extensive hands-on experience in cell culture, assay development, and therapeutic research. That scientific foundation gave me a ...

Exelixis, Inc. (NASDAQ:EXEL) is one of the 15 Set-It-and-Forget-It Stocks to Buy in 2026. RBC Capital Lowers Exelixis (EXEL) Price Target to $43 On March 2, 2026, Exelixis, Inc. (NASDAQ:EXEL) saw its price target from RBC Capital lowered from $46 to $43. The firm’s Sector Perform rating was maintained on the stock. In a research note, RBC Capital pointed out that after the reporting of the data from the HIF-2alpha inhibitors study by Exelixis, Inc. (NASDAQ:EXEL)’s competitor Merck (MRK), the share value ...

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is one of the 15 Set-It-and-Forget-It Stocks to Buy in 2026. Wells Fargo Raises Vertex Pharmaceuticals (VRTX) Price Target to $550 On March 19, 2026, Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) saw its price target raised by Wells Fargo from $515 to $550. The firm’s analyst kept an Overweight rating on the shares. Wells Fargo anticipates a threefold growth in the market for the generalized Myasthenia Gravis (gMG), reaching $20 billion globally by 20 ...

One of the top-performing healthcare stocks mid-week was Corcept Therapeutics (CORT 2.41%), and it was little wonder -- the company was granted U.S. Food and Drug Administration (FDA) approval for its leading drug candidate.The double-digit pop Corcept experienced wasn't sustainable, as some investors booked quick profits after learning of the nod. Still, the stock landed in positive territory, posting a gain of just under 9% over the course of the week, according to data compiled by S&P Global Market Intel ...

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

SAN FRANCISCO, March 27, 2026 (GLOBE NEWSWIRE) -- ImmunityBio, Inc. (NASDAQ: IBRX) faces a securities class action lawsuit which seeks to represent investors who purchased or otherwise acquired ImmunityBio securities between January 19, 2026 and March 24, 2026. The lawsuit follows news that the FDA sent a warning letter to the company concerning claims made by its executive chairman and Chief Scientific and Medical Officer (Dr. Patrick Soon-Shiong) regarding ImmunityBio’s lead biologic product (Anktiva), wh ...

Investor Notice: Robbins LLP Informs Investors of the Vital Farms, Inc. Class Action Lawsuit Mar 27, 2026 6:35 PM Eastern Daylight Time Investor Notice: Robbins LLP Informs Investors of the Vital Farms, Inc. Class Action Lawsuit Share SAN DIEGO--(BUSINESS WIRE)-- Robbins LLPinforms stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Vital Farms, Inc. (NASDAQ: VITL) securities between May 8, 2025 and February 26, 2026. Vital Farms purports to be an ethica ...